Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma
NCT07694973Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of inavolisib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Fudan University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
inavolisib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07694973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694973.